Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03985696 | Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas(ExoReBLy) | completed | N/A | 90 | University Hospital, LimogesOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03283917 | Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis | completed | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03568461 |
| Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma(ELARA) |
| completed |
| Phase 2 |
| 98 |
| Novartis PharmaceuticalsINDUSTRY |
| 12 |
| Jul 9, 2026 |
| clinicaltrials |
| NCT05742217 | A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases(MUST) | completed | — | 121 | PfizerINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06483139 | Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy | completed | — | 549 | Brigham and Women's HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04837222 | A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma | completed | — | 1,000 | TakedaINDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06182163 | Reduce Sedentary Time in Acute Lymphoblastic Leukemia(ReSeT in ALL) | completed | N/A | 20 | Children's Hospital Los AngelesOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07689006 | Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens | completed | — | 341 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05139225 | A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma | completed | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06472778 | A Real-world Study in Participants With Smoldering Multiple Myeloma | completed | — | 408 | Janssen-Cilag Ltd.INDUSTRY | 5 | Jul 6, 2026 | clinicaltrials |
| NCT04000880 | Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health(AMPLIFY) | completed | N/A | 603 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05230004 | Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate Growth | completed | N/A | 35 | University of PennsylvaniaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05824585 | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 | 17 | Dizal PharmaceuticalsINDUSTRY | 2 | Jul 2, 2026 | clinicaltrials |
| NCT06203912 | Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 3 | Elvira UmyarovaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05653271 | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | completed | Phase 1 | 16 | Acepodia Biotech, Inc.INDUSTRY | 3 | Jun 30, 2026 | clinicaltrials |
| NCT06694779 | Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study(PREDIC-TO) | completed | — | 1,504 | Fondazione IRCCS San Gerardo dei TintoriOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04168788 | Pharmacogenetic Study of Antimitotic Therapies Involved in Hepatic VOD in Children With Nephroblastoma or ALL(MVO) | completed | N/A | 85 | University Hospital, AngersOTHER_GOV | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04975698 | HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903(BMTCTN1903) | completed | Phase 2 | 12 | Catherine BollardNIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT01209871 | Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma | completed | Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 111 | AmgenINDUSTRY | 24 | Jun 26, 2026 | clinicaltrials |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04292626 | Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose | completed | Phase 1 | 16 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05455931 | Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)(PROSPER) | completed | — | 73 | Kyowa Kirin Pharmaceutical Development LtdINDUSTRY | 6 | Jun 26, 2026 | clinicaltrials |
| NCT07198087 | A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants | completed | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03323151 | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma(PrE0404) | completed | Phase 1 / Phase 2 | 43 | PrECOG, LLC.OTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05440409 | CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL | completed | — | 57 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT01657331 | Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)(SGN+Benda) | completed | Phase 1 / Phase 2 | 65 | Columbia UniversityOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT00408005 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | completed | Phase 3 | 1,895 | National Cancer Institute (NCI)NIH | 5 | Jun 23, 2026 | clinicaltrials |
| NCT01415882 | Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | completed | Phase 2 | 165 | Mayo ClinicOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03901963 | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant(AURIGA) | completed | Phase 3 | 200 | Janssen Research & Development, LLCINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT04252508 | Impact of a Double-reading Animated Film (Child, Parents) in Preoperative on the Anxiety of Children Upon Arrival at the Operating Room(VERAPOP) | completed | N/A | 80 | University Hospital, BordeauxOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03651128 | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)(KarMMa-3) | completed | Phase 3 | 386 | CelgeneINDUSTRY | 13 | Jun 22, 2026 | clinicaltrials |
| NCT00081874 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04045561 | Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy Primocure | completed | — | 10 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01242930 | Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | completed | Phase 2 | 13 | Geron CorporationINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05422521 | Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma(CART-Omic) | completed | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01644799 | Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma | completed | Phase 1 | 8 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT01838434 | Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 1 | 106 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03602612 | T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05818644 | Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children(HEPATIC) | completed | — | 583 | University Medical Center GroningenOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03447808 | Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | completed | Phase 1 | 15 | Jennifer WoyachOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03839459 | Denosumab for Smoldering Multiple Myeloma | completed | Phase 2 | 20 | University of RochesterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04737265 | Pilot Study of an NTproBNP Guided Strategy of Cardioprotection(NTproBNP-Guide) | completed | Phase 1 / Phase 2 | 108 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02232516 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03570892 | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma(BELINDA) | completed | Phase 3 | 330 | Novartis PharmaceuticalsINDUSTRY | 18 | Jun 12, 2026 | clinicaltrials |
| NCT04113226 | Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma(Relyage) | completed | Phase 2 | 1 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07644351 | A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients(ASCERTAIN) | completed | — | 37 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2026source: clinicaltrials